NEUTRALIZING AND COMPLEMENT-DEPENDENT ENHANCING ANTIBODIES IN DIFFERENT STAGES OF HIV-INFECTION

被引:34
作者
TOTH, FD
SZABO, B
UJHELYI, E
PALOCZI, K
HORVATH, A
FUST, G
KISS, J
BANHEGYI, D
HOLLAN, SR
机构
[1] NATL INST HAEMATOL & BLOOD TRANSFUS,DAROCZI UT 24,POB 44,H-1502 BUDAPEST,HUNGARY
[2] LASZLO CENT HOSP INFECT DIS,BUDAPEST,HUNGARY
[3] LAJOS KOSSUTH UNIV,SCH MED,INST MICROBIOL,H-4010 DEBRECEN,HUNGARY
[4] NATL INST DERMATOL & VENEROL,BUDAPEST,HUNGARY
关键词
NEUTRALIZING AND ENHANCING HIV ANTIBODIES; AIDS; ARC; PROGNOSIS; COMPLEMENT RECEPTORS; MT-4;
D O I
10.1097/00002030-199103000-00003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Reclustering and indirect immunofluorescence assays on MT-4 cells [carrying both CD4 and complement receptor type 2 (CR2)] were used to measure neutralizing and enhancing antibodies in sera obtained from HIV-1-infected individuals. Heat-inactivated sera were tested before and after mixing 1:1 with fresh seronegative human serum. Using heated samples, neutralizing antibodies were found in 20 out of 20 and 11 out of 19 serum samples of asymptomatic and symptomatic [AIDS, AIDS-related complex (ARC)] HIV-seropositive patients, respectively. In complement-restored samples, neutralizing activity was found in eight sera of asymptomatic patients and in none of the sea of AIDS and ARC patients; enhancing activity could be detected in four and 12 sera, respectively. A significant positive correlation was observed between the titres of neutralizing antibodies measured in the complement-restored samples and the absolute number of CD4+ lymphocytes. These findings indicate that the appearance of complement-dependent enhancing antibodies coincident with the loss of neutralizing antibodies may indicate a poor prognosis in HIV infection.
引用
收藏
页码:263 / 268
页数:6
相关论文
共 26 条
[1]   HIV NEUTRALIZING ANTIBODIES - DEVELOPMENT AND ASSOCIATION WITH HIV RELATED DISEASE [J].
ARENDRUP, M ;
ULRICH, K ;
NIELSEN, JO ;
LINDHARDT, BO ;
KUSK, P ;
MATHIESEN, LR ;
PEDERSEN, C ;
KROGSGAARD, K .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1989, 21 (01) :19-26
[2]  
BOTTIGER B, 1988, CLIN EXP IMMUNOL, V73, P339
[3]  
GRAS G, 1988, LANCET, V1, P1285
[4]  
HOMSY J, 1988, LANCET, V1, P1285
[5]   SERUM ENHANCEMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION CORRELATES WITH DISEASE IN HIV-INFECTED INDIVIDUALS [J].
HOMSY, J ;
MEYER, M ;
LEVY, JA .
JOURNAL OF VIROLOGY, 1990, 64 (04) :1437-1440
[6]   AIDS-ASSOCIATED RETROVIRUSES (ARV) CAN PRODUCTIVELY INFECT OTHER CELLS BESIDES HUMAN T-HELPER CELLS [J].
LEVY, JA ;
SHIMABUKURO, J ;
MCHUGH, T ;
CASAVANT, C ;
STITES, D ;
OSHIRO, L .
VIROLOGY, 1985, 147 (02) :441-448
[7]  
MATSUO Y, 1989, LEUKOCYTE TYPING 4 W, P299
[8]   ANALYSIS OF C3-RECEPTOR ACTIVITY ON HUMAN LYMPHOCYTES-B AND ISOLATION OF THE COMPLEMENT RECEPTOR TYPE-2 (CR-2) [J].
MICKLEM, KJ ;
SIM, RB ;
SIM, E .
BIOCHEMICAL JOURNAL, 1984, 224 (01) :75-86
[9]   ANTIBODY-DEPENDENT ENHANCEMENT OF SIMIAN IMMUNODEFICIENCY VIRUS (SIV) INFECTION INVITRO BY PLASMA FROM SIV-INFECTED RHESUS MACAQUES [J].
MONTEFIORI, DC ;
ROBINSON, WE ;
HIRSCH, VM ;
MODLISZEWSKI, A ;
MITCHELL, WM ;
JOHNSON, PR .
JOURNAL OF VIROLOGY, 1990, 64 (01) :113-119
[10]   SENSITIVE AND RAPID ASSAY ON MT-4 CELLS FOR DETECTION OF ANTIVIRAL COMPOUNDS AGAINST THE AIDS VIRUS [J].
PAUWELS, R ;
DECLERCQ, E ;
DESMYTER, J ;
BALZARINI, J ;
GOUBAU, P ;
HERDEWIJN, P ;
VANDERHAEGHE, H ;
VANDEPUTTE, M .
JOURNAL OF VIROLOGICAL METHODS, 1987, 16 (03) :171-185